ReShape Lifesciences™ Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System in Peer Reviewed, Frontiers in NeuroScience
25. Oktober 2022 08:30 ET
|
ReShape Lifesciences Inc
Data Shows ReShape’s DBSN™ System has Promise as a Novel, Adjustable and Localized Approach to Treat Type 2 Diabetes SAN CLEMENTE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™...
ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)
20. Oktober 2022 08:30 ET
|
ReShape Lifesciences Inc
Active ASMBS Members, Comprised of Lap-Band® Clinical Experts, Participated in a Consensus Process to Yield Recommendations for Optimal Aftercare ASMBS Reasserts Endorsement of the...
ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
22. September 2022 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...
ReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech Conference
14. September 2022 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul...
ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations
23. August 2022 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...
ReShape Lifesciences™ Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15. August 2022 16:05 ET
|
ReShape Lifesciences Inc
Second Quarter Revenues Increased 19% Sequentially, Indicating DTC Campaign Continues to Drive Demand for Lap-Band® Procedures Conference Call to be Held at 4:30 pm ET Today SAN CLEMENTE,...
ReShape Lifesciences™ to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
10. August 2022 16:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that...
ReShape Lifesciences™ Receives FDA 510(k) Clearance for the GIBI HD™ Calibration Tubes for use in Gastric and Bariatric Procedures
10. August 2022 12:05 ET
|
ReShape Lifesciences Inc
New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric Banding Company to Introduce Product at...
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer
27. Juli 2022 16:05 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its...
ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds
17. Juni 2022 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that...